Risperidone for Schizophrenia

"This clinical trial seeks 90 participants with schizophrenia spectrum and other psychotic disorders aged between 18-35. Qualified candidates must meet these criteria to be considered for the study."

"Affirmative. Clinicaltrials.gov discloses that this research study is actively recruiting patients, which first commenced on September 15th 2017 and has been recently modified on July 28th 2022. A total of 90 participants are being sought from one center."

"Risperidone is typically employed to treat acute coryza and multiple other afflictions such as autistic disorder, bipolar disorder, and irritability."

"There is ample evidence to suggest the safety of Risperidone, leading our team to assign it a score of 3 due to its status as an approved Phase 4 treatment."

"Affirmative. Clinicaltrials.gov reveals that this trial, first posted on September 15th 2017, is currently recruiting individuals for participation. The clinical team has reserved a quota of 90 patients from one medical centre to partake in the study."

"This clinical trial will measure the Change in biomarkers reflecting treatment response: Medial Prefrontal Cortex (MPFC) Glutamate, Changes in motor symptomatology: Abnormal Involuntary Movement Scale (AIMS), Recreational Substances Used by Patients as Recorded by the Substance Use Questionnaire and Changes in clinical severity: Clinical Global Impression Scale over a Baseline to 4th week of treatment time frame. Secondary objectives include analysis of symptoms related to tardive dyskinesia on an AIMS scale ranging from 0-28, whether substance use has increased or decreased since initial assessment based off responses to the"

"Per the stated requirements, individuals aged 18 to 35 are eligible for inclusion in this research."

"Currently, 17 trials are underway to research the efficacy of Risperidone. One is in Phase 3 and 139 sites have been designated as testing locations; most of which reside within Toronto, Ontario."